Schering Plough and Sepracor have settled a patent dispute with Indian generics maker Dr. Reddy's over Clarinex. The settlement brings forward the end of patent exclusivity on Clarinex to 2012. Previously, the assumption had been that Schering's exclusivity with Clarinex would last until 2020.
Clarinex does not contain a decongestant (that’s Clarinex-D) and therefore does not cause drowsiness. Clarinex is known as the first antihistamine to state in its labeling that grapefruit juice does not affect the absorption of the active ingredient.
Amanda Jones is a licensed veterinary technician and an avid researcher of human allergy relief products including Clarinex. She runs a successful website dedicated to debunking various allergy relief products for the benefit of the consumer.
